MP491/6-Undergraduate Research Project Proposal 1. Title ... - UCSI

More documents

Recommendations

Info

6. Title: Evaluation of hypoglycemic activity of Limonia acidissima bark extract. Supervisor(s) Main: Mr. Nalamolu Koteswara Rao. Co- : Dr. Gabriel Akowuah. Objective(s) 1. Evaluation of hypoglycemic activity of Limonia acidissima bark extract using streptozotocin-induced diabetic rats. Abstract Diabetes mellitus is an endocrine disorder that is characterized by hyperglycemia and a number of complications such as nephropathy, retinopathy, neuropathy, and cardiopathy. A worldwide survey showed that nearly 10% of the population is affected by this disorder. Modern treatment of diabetes based on oral hypoglycaemics (sulphonylureas, biguanides and –glucosidase inhibitors) and insulin showed an adverse effect with relatively high rates of secondary failure. As an alternative approach, scientific investigation on traditional remedies has led to the discovery of herbal drugs for the treatment of diabetes mellitus. An estimated 90% of the population in rural areas of developing countries still relies on traditional medicines for their primary health care. Limonia acidissima (Rutaceae), commonly known as wood apple (locally named belinggai), is distributed in dry warm regions of Burma, India, Malaya and Sri Lanka. Traditionally, the constituents (in paste form) from the bark of L. acidissima is mixed with water and applied mainly to the face for removal of small spots or lesions for a smooth, fair and well-textured complexion. It is also known to protect against skin cancer by blocking UV rays. Oil and constituents derived from the leaf, bark, root and fruit pulp are used against snake bites, and as fungicides, bactericides and insecticides. As constituents of bark extract from this plant have been used in traditional medicine for diabetes management, we are interested to find out the value of its hypoglycemic activity. Therefore, the evaluation of hypoglycemic activity of bark extract of L. acidissima will be useful in illustrating its mechanism of action and promote its commercial development. 7. Title: Patient-Focused Medication Adherence Type-II Diabetes Mellitus Supervisor(s) Main: Assoc. Prof. Dr. Yeong Siew Wei Co- : None Objectives: 1. To evaluate the effectiveness of a patient-focused tool in improving medication adherence among Type-II diabetic patients. 2. To develop a patient Medication Adherence Plan (MAP) for improving medication adherence in diabetes mellitus. 4
Abstract Definition of the expected results: The effectiveness of the patient-focused tool will be evaluated by analysing data with various statistical tools. A significant level will be set at < 0.05. The patient-focused tool from the project will be refined and to be suggested to the relevant authority as a practical tool for improving medication adherence in the practical settings. Patients and practitioners Knowledge of effective communication from this project will translate into better patientpractitioner’s communication. This will help in enhancing the therapeutic effectiveness of therapy. Patients would be able to identify and recognize their roles in taking charge of their own health. Practitioners would gain important skills and tools in effectively communicating to their patients on medication adherence. 8. Title: Development of improved (high performance thin layer chromatography) HPTLC method for estimation of levofloxacin in dosage forms. Supervisor(s) Main: A. Mohamed Saleem. Co- : None. Fig. 1. Levofloxacin [(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7- oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid] CAS Registry Number: 100986-85-4 Chemical Formula: C 18 H 20 FN 3 O 4 Molecular Weight: 361.37 Abstract During the last two decades, quinolones have become an increasingly important and expanding family of antibacterial agents. The quinolone, levofloxacin (Fig. 1) have activity against both Gram(+) and Gram(–) bacteria (aerobic and anaerobic) through inhibition of the bacterial enzyme (DNA gyrase) that maintains the super-twisted helical structure of DNA. Levofloxacin is administered to patients with urinary, respiratory or cutaneous infections in 500 mg day –1 dose. 5
Page 1 and 2: MP491/6-Undergraduate Research Proj
Page 3: 4. Title: Toxicity effects of sub-c
Page 7 and 8: the appropriate registration proced
Page 9: Stilbene derivatives (A) and (B) pr

MP491/6-Undergraduate Research Project Proposal 1. Title ... - UCSI

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?